Sargent Investment Group LLC lowered its holdings in Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB – Free Report) by 3.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,492,000 shares of the company’s stock after selling 118,500 shares during the quarter. Sargent Investment Group LLC owned about 1.39% of Matinas BioPharma worth $553,000 as of its most recent filing with the SEC.
Several other large investors also recently made changes to their positions in the business. Private Advisor Group LLC increased its stake in shares of Matinas BioPharma by 31.1% in the 4th quarter. Private Advisor Group LLC now owns 337,330 shares of the company’s stock valued at $73,000 after buying an additional 80,000 shares during the period. Towercrest Capital Management acquired a new position in Matinas BioPharma during the 2nd quarter valued at about $299,000. Finally, Alliance Wealth Management Group bought a new position in shares of Matinas BioPharma in the 2nd quarter valued at about $299,000. Institutional investors own 11.77% of the company’s stock.
Matinas BioPharma Stock Performance
NYSEAMERICAN:MTNB opened at $3.71 on Tuesday. Matinas BioPharma Holdings, Inc. has a 12-month low of $3.28 and a 12-month high of $44.50. The firm has a market capitalization of $18.62 million, a PE ratio of -30.92 and a beta of 1.65.
Matinas BioPharma Company Profile
Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.
See Also
- Five stocks we like better than Matinas BioPharma
- What Are Trending Stocks? Trending Stocks Explained
- Why Rate Cuts Could Trigger a ‘Sell the News’ Event for Stocks
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Top 3 Key Investment Trends You Can’t Ignore Ahead of Rate Cuts
- NYSE Stocks Give Investors a Variety of Quality Options
- 3 Stocks the Market Is Willing to Overpay for Right Now
Want to see what other hedge funds are holding MTNB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB – Free Report).
Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.